TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis C$1.75 +0.05 (+2.94%) As of 03:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesBuy This Stock About Aptose Biosciences Stock (TSE:APS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aptose Biosciences alerts:Sign Up Key Stats Today's RangeC$1.75▼C$1.7950-Day RangeC$1.09▼C$2.5052-Week RangeC$1.02▼C$23.10Volume707 shsAverage Volume5,449 shsMarket CapitalizationC$75.35 millionP/E RatioN/ADividend Yield0.39%Price TargetN/AConsensus RatingStrong Buy Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APS Stock News HeadlinesAptose Biosciences Inc. (APS.TO) - Yahoo FinanceJuly 3, 2025 | ca.finance.yahoo.comAptose Announces Deferral of Interest Payment - MorningstarJuly 2, 2025 | morningstar.comMFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Aptose Biosciences, Inc.: Aptose Provides Corporate UpdatesJune 17, 2025 | finanznachrichten.deAptose Biosciences shares to delist from Nasdaq as of April 2April 2, 2025 | markets.businessinsider.comAptose Biosciences' Shares Tumble Ahead of Nasdaq DelistingApril 2, 2025 | marketwatch.comAptose shares tumble following Nasdaq delisting decisionApril 1, 2025 | in.investing.comAptose Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementsMarch 19, 2025 | nasdaq.comSee More Headlines APS Stock Analysis - Frequently Asked Questions How have APS shares performed this year? Aptose Biosciences' stock was trading at C$9.75 at the beginning of the year. Since then, APS shares have decreased by 82.1% and is now trading at C$1.75. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split on the morning of Wednesday, February 26th 2025.The 1-30 reverse split was announced on Wednesday, February 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), VistaGen Therapeutics (VTGN), BlackBerry (BB) and Micron Technology (MU). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($5.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$154.69 million Net MarginsN/A Pretax MarginN/A Return on Equity1,017.48% Return on Assets-136.29% Debt Debt-to-Equity Ratio-117.37 Current Ratio1.05 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.12 per share Price / Cash Flow1.60 Book ValueC($0.92) per share Price / Book-1.95Miscellaneous Outstanding Shares43,058,192Free FloatN/AMarket CapC$77.07 million OptionableNot Optionable Beta1.36 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (TSE:APS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly tak...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.